Xtant Medical Holdings logo

Xtant Medical HoldingsNYSE American: XTNT

Profile

Sector:

Healthcare

Country:

United States

IPO:

01 July 2010

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$73.64 M
-59%vs. 3y high
40%vs. sector
-vs. 3y high
-vs. sector
-70%vs. 3y high
51%vs. sector
-74%vs. 3y high
17%vs. sector

Price

after hours | Thu, 24 Oct 2024 23:31:14 GMT
$0.53$0.00(0.00%)

Dividend

No data over the past 3 years
$29.94 M$29.30 M
$29.94 M-$3.86 M

Analysts recommendations

Institutional Ownership

XTNT Latest News

Xtant Medical Holdings, Inc. (XTNT) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ET Company Participants Brett Maas - IR Sean Browne - President and CEO Scott Neils - CFO Conference Call Participants Ryan Zimmerman - BTIG Chase Knickerbocker - Craig-Hallum Capital Operator Welcome to the Xtant Medical Holdings, Inc. Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to your host, Brett Maas, IR.

Xtant Medical Announces Closing of $5.0 Million Private Placement
accesswire.com09 August 2024 Sentiment: POSITIVE

BELGRADE, MT / ACCESSWIRE / August 9, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the closing of its previously announced $5.0 million private placement with an existing institutional investor. The Company sold 7,812,500 shares of common stock at a purchase price of $0.64 per share.

Xtant Medical Announces $5.0 Million Private Placement
accesswire.com08 August 2024 Sentiment: POSITIVE

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it has entered into a securities purchase agreement with an existing institutional investor to sell shares of its common stock in a private placement. The Company agreed to issue an aggregate of 7,812,500 shares of common stock at a purchase price of $0.64 per share, resulting in gross proceeds of $5.0 million.

Xtant Medical to Host Second Quarter 2024 Financial Results Earnings Conference call on August 9, 2024
accesswire.com08 August 2024 Sentiment: POSITIVE

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 8, 2024. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Friday, August 9, 2024, at 9:00 AM ET to review results.

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%
accesswire.com08 August 2024 Sentiment: POSITIVE

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $29.9 million, up 48%, compared to the prior year quarter Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter Net loss of $3.9 million compared to $2.2 million in the year ago quarter Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter Recent Business Highlights Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter Signed 15 new distributors in the second quarter Awarded 20 IDN contracts in the second quarter Entered into a $5.0 million private placement on August 7, 2024 Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024.

Xtant Medical to Participate in Upcoming Investor Conferences
GlobeNewsWire09 November 2023 Sentiment: NEUTRAL

BELGRADE, Mont., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:

Xtant Medical Holdings, Inc. (XTNT) Q1 2023 Earnings Call Transcript
Seeking Alpha06 May 2023 Sentiment: POSITIVE

Xtant Medical Holdings, Inc. (NYSE:XTNT ) Q1 2023 Earnings Conference Call May 4, 2023 9:00 AM ET Company Participants Matt Steinberg - IR Sean Browne - CEO Scott Neils - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Kyle Rose - Canaccord Genuity Operator Greetings. You're welcome Xtant Medical's Q1 2023 financial results call.

What type of business is Xtant Medical Holdings?

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.

What sector is Xtant Medical Holdings in?

Xtant Medical Holdings is in the Healthcare sector

What industry is Xtant Medical Holdings in?

Xtant Medical Holdings is in the Medical Devices industry

What country is Xtant Medical Holdings from?

Xtant Medical Holdings is headquartered in United States

When did Xtant Medical Holdings go public?

Xtant Medical Holdings initial public offering (IPO) was on 01 July 2010

What is Xtant Medical Holdings website?

https://www.xtantmedical.com

Is Xtant Medical Holdings in the S&P 500?

No, Xtant Medical Holdings is not included in the S&P 500 index

Is Xtant Medical Holdings in the NASDAQ 100?

No, Xtant Medical Holdings is not included in the NASDAQ 100 index

Is Xtant Medical Holdings in the Dow Jones?

No, Xtant Medical Holdings is not included in the Dow Jones index

When was Xtant Medical Holdings the previous earnings report?

No data

When does Xtant Medical Holdings earnings report?

The next expected earnings date for Xtant Medical Holdings is 08 November 2024